within Pharmacolibrary.Drugs.ATC.N;

model N03AX14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.995,
    Cl             = 1.6e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.020166666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Levetiracetam is an anticonvulsant medication used primarily for the treatment of epilepsy. It is indicated as adjunctive therapy for partial onset seizures, myoclonic seizures, and tonic-clonic seizures in adults and children. Levetiracetam is widely approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Radtke, RA (2001). Pharmacokinetics of levetiracetam. <i>Epilepsia</i> 42 Suppl 4 24–27. DOI:<a href=\"https://doi.org/10.1046/j.1528-1157.2001.0420s4024.x\">10.1046/j.1528-1157.2001.0420s4024.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11564121/\">https://pubmed.ncbi.nlm.nih.gov/11564121</a></p></li><li><p>Barnard, L, et al., &amp; Boothe, DM (2018). Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats. <i>Journal of veterinary internal medicine</i> 32(1) 348–351. DOI:<a href=\"https://doi.org/10.1111/jvim.14863\">10.1111/jvim.14863</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29114943/\">https://pubmed.ncbi.nlm.nih.gov/29114943</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX14;
